Even After My Lung Transplant, Fall Continues to Taunt Me

First Patient Enrolled in Phase 3 Trial Testing BI 1015550

Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). The trial is part of the FIBRONEER global program, which also includes FIBRONEER-ILD, a similar Phase…

AbbVie Gets Experimental IPF Treatment DJS-002 in Acquisition

AbbVie’s portfolio of antibodies for the potential treatment of idiopathic pulmonary fibrosis (IPF) now includes DJS-002 — a first-in-class antibody directed against lysophosphatidic acid receptor-1 (LPAR1), a protein thought to drive the progression of IPF and other fibrotic diseases. This was made possible by AbbVie’s estimated $250 million acquisition of…

How Mindfulness Helps Me on My IPF Journey

The benefits of mindfulness are becoming more prevalent in literature. A quick search on social media or Google will reveal not only the importance of practicing mindfulness regularly, but also an abundance of self-led practice videos and articles about the topic. However, I wish the benefits of mindfulness for those…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums